Cancer glossary
CA 15-3: the breast cancer tumor marker — when to test and how to read it
CA 15-3 is a tumor marker in breast cancer. Why it isn't used for screening, when it helps follow metastatic disease, and why a rise doesn't always mean progression.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
In short
CA 15-3 is a protein that breast cancer cells can release. It is used mainly in metastatic cancer, to follow the response to treatment.
How it appears in your report
- ‘CA 15-3 18 U/mL (normal up to 25–30)’.
- ‘CA 15-3 — 140 U/mL, down from 310’.
What it means
According to the US National Cancer Institute, CA 15-3 is used to assess whether treatment is working or whether breast cancer has come back. It is not suitable for screening or diagnosis: in early stages it is often normal, and it can rise in benign breast disease, liver disease and other conditions.
What matters is the trend from the same lab. A steady rise over several tests in a row is a reason for an unscheduled CT, but decisions to change treatment are made on scans and symptoms, not on one marker. A temporary rise (‘flare’) can happen at the start of a new treatment.
Does it affect treatment
Only together with CT, PET-CT and symptoms. A tumor marker on its own is not a reason to change the line of therapy.
Questions to ask your doctor
- Was my CA 15-3 raised before treatment — is it informative for me?
- How often should I test, and in which lab?
- What rise would justify an unscheduled CT?
Sources
- Tumor Markers in Common Use — National Cancer Institute
- Tumor Markers — National Cancer Institute
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
